Home Cart Sign in  
Chemical Structure| 267243-28-7 Chemical Structure| 267243-28-7

Structure of Canertinib
CAS No.: 267243-28-7

Chemical Structure| 267243-28-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Canertinib is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4.

Synonyms: CI-1033; PD-183805

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Canertinib

CAS No. :267243-28-7
Formula : C24H25ClFN5O3
M.W : 485.94
SMILES Code : C=CC(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OCCCN4CCOCC4)=O
Synonyms :
CI-1033; PD-183805
MDL No. :MFCD09837878

Safety of Canertinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Canertinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:1.5 nM

  • HER2/ErbB2

    ErbB2, IC50:9.0 nM

  • HER2

    ErbB2, IC50:9.0 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
BSC-40 cells 10 μM 4 days Inhibition of secondary viral spreading in BSC-40 cells, significantly reducing plaque and comet formation. PMC546427
VERO-E6 cells 10 μM 4 days Inhibition of secondary viral spreading in VERO-E6 cells, significantly reducing EEV formation. PMC546427
GBM6 1 μM and 10 μM 6 hours Evaluate the effect of EGFR kinase inhibition, results show that Canertinib at 10 μM significantly inhibits EGFR kinase activity and induces apoptosis. PMC9159289
GBM6, GBM39, GBM59 10 μM 24 hours Evaluate apoptosis, results show that 10 μM Canertinib significantly increases apoptosis. PMC9159289
SK-N-SH cells 3 μM 48 hours Induced apoptosis, increased the proportion of subdiploid cells PMC2923448
SK-N-AS cells 5 μM Induced apoptosis PMC10682029

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice SCID mice Peritoneal injection 200 mg/kg Single dose To evaluate the therapeutic effect of Canertinib on MAN2A1–FER positive tumors, results showed that Canertinib significantly inhibited tumor growth and metastasis. PMC5572118
Mice Lethal vaccinia virus pneumonia model Intraperitoneal injection 30 mg/kg Daily from P5–P7, then every alternate day from P9–P13 In a lethal vaccinia virus pneumonia model, CI-1033 alone promotes survival of animals, augments systemic T cell immunity and, in conjunction with a single dose of anti-L1R mAb, fosters virtually complete viral clearance of the lungs of infected mice by the eighth day after infection. PMC546427
Mice MET KO mice Dietary administration 50 mg/kg Once daily for 8 days Combined use of Canertinib with MET KO significantly attenuated TCPOBOP-induced hepatocyte proliferation and hepatomegaly PMC6289897
Mice FFD-induced MASLD model Oral 30 mg/kg twice a day for 2 weeks Canertinib significantly reduced steatosis in EGFR-KO mice, suggesting the compensatory roles of other ErbB receptors in supporting MASLD PMC11387264
Mice GBM6 PDX model Oral 75 mg/kg single dose 3 hours prior Evaluate the in vivo anti-tumor effect of Canertinib, results show that 100 mg/kg Canertinib significantly inhibits tumor growth. PMC9159289
BALB/c-Nude mice H1975 xenograft model Oral 0.1 or 1 mg/kg body weight/day Once To evaluate the antitumor activity of Canertinib in the H1975 xenograft model. Results showed that Canertinib significantly inhibited tumor growth but was accompanied by significant body weight loss in animals. PMC3556939
NOD-SCID-IL2R gamma knockout mice Neuroblastoma xenograft model Oral 0.1 mg/kg single injection, amphetamine administered 30 minutes later Significantly reduced tumor growth PMC2923448

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00174356 Carcinoma, Non-Small Cell Lung Phase 1 Completed - United States, Florida ... More >> Pfizer Investigational Site Tampa, Florida, United States, 33612 United States, Illinois Pfizer Investigational Site Park Ridge, Illinois, United States, 60068 Pfizer Investigational Site Skokie, Illinois, United States, 60076 United States, Kentucky Pfizer Investigational Site Louisville, Kentucky, United States, 40202 Pfizer Investigational Site Louisville, Kentucky, United States, 40207 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77030 Canada, Ontario Pfizer Investigational Site Hamilton, Ontario, Canada, L8V 5C2 Less <<
NCT00050830 Lung Neoplasms Phase 2 Completed - -
NCT00051051 Breast Neoplasms Phase 2 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.29mL

2.06mL

1.03mL

20.58mL

4.12mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories